Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, USA.
Neurology. 2013 Feb 5;80(6):561-8. doi: 10.1212/WNL.0b013e3182815547. Epub 2013 Jan 16.
To characterize the presenting symptoms and signs of patients clinically diagnosed with behavioral variant frontotemporal dementia (bvFTD) and who had different neuropathologic findings on autopsy.
This study reviewed all patients entered as clinical bvFTD in the National Alzheimer's Coordinating Center's database and who had both clinical and neuropathologic data from 2005 to 2011. Among the 107 patients identified, 95 had unambiguous pathologic findings, including 74 with frontotemporal lobar degeneration (bvFTD-FTLD) and 21 with Alzheimer disease (bvFTD-AD). The patients with bvFTD-FTLD were further subdivided into τ-positive (n = 23) or τ-negative (n = 51) histopathology subgroups. Presenting clinical signs and symptoms were compared between these neuropathologic groups.
The patients with bvFTD-FTLD were significantly more likely than patients with bvFTD-AD to have initially predominant personality changes and poor judgment/decision-making. In contrast, patients with bvFTD-AD were more likely than patients with bvFTD-FTLD to have memory difficulty and delusions/hallucinations and agitation. Within the bvFTD-FTLD group, the τ-positive subgroup had more patients with initial behavioral problems and personality change than the τ-negative subgroup, who, in turn, had more patients with initial cognitive impairment and speech problems.
During life, patients with AD pathology may be misdiagnosed with bvFTD if they have an early age at onset and prominent neuropsychiatric features despite having greater memory difficulties and more intact personality and executive functions than patients with bvFTD-FTLD. Among those with FTLD pathology, patients with τ-positive bvFTD were likely to present with behavior/personality changes. These findings offer clues for antemortem recognition of neuropathologic subtypes of bvFTD.
描述临床上诊断为行为变异额颞叶痴呆(bvFTD)且尸检时具有不同神经病理学发现的患者的首发症状和体征。
本研究回顾了 2005 年至 2011 年期间国家阿尔茨海默病协调中心数据库中所有被临床诊断为 bvFTD 的患者,并对其进行了临床和神经病理学数据的分析。在确定的 107 名患者中,有 95 名患者具有明确的病理发现,其中 74 名患者患有额颞叶变性(bvFTD-FTLD),21 名患者患有阿尔茨海默病(bvFTD-AD)。将 bvFTD-FTLD 患者进一步分为 tau 阳性(n=23)或 tau 阴性(n=51)组织病理学亚组。比较这些神经病理学组之间的首发临床症状和体征。
与 bvFTD-AD 患者相比,bvFTD-FTLD 患者更有可能最初出现明显的人格改变和判断力/决策能力下降。相比之下,bvFTD-AD 患者更有可能出现记忆障碍、妄想/幻觉和激越,而 bvFTD-FTLD 患者更有可能出现这些症状。在 bvFTD-FTLD 组中,tau 阳性亚组比 tau 阴性亚组有更多的患者最初出现行为问题和人格改变,而 tau 阴性亚组则有更多的患者最初出现认知障碍和言语问题。
在有 AD 病理的患者中,如果发病年龄较早且存在突出的神经精神特征,尽管他们的记忆障碍更严重,人格和执行功能更完整,但可能会被误诊为 bvFTD。在具有 FTLD 病理的患者中,tau 阳性的 bvFTD 患者可能会出现行为/人格改变。这些发现为生前识别 bvFTD 的神经病理学亚型提供了线索。